Navigate Fool.com
Will RCPT beat
the market?



Community Rating: 2 Stars: Unattractive

35.99 0.00 (0.00%)

Quote as of

Extended Hours: $35.99 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $34.77
Previous Close $35.99
Daily Range $33.90 - $37.26
52-Week Range $13.00 - $55.00
Market Cap $797.8M
P/E Ratio -8.28
Dividend (Yield) $0.00 (0.0%)
Volume 192,296
Average Daily Volume 353,789
Current FY EPS -$4.04

How do you think RCPT
will perform against the market?

Top RCPT Bull/Bear Pitches


There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!


There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

Is Teva Pharmaceutical Industries Ltd Turning a Corner?

Teva has rebounded sharply as management addresses multiple Street concerns

Friday's ETF Movers: GDXJ, XBI

3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos

Although biotech in general has been having a rough go, these three stocks are falling like a knife.

BioMed Realty Trust Leases Space To Life Science Firms

Why Receptos Inc. Shares Briefly Popped

Receptos shares jump following the company's fourth-quarter earnings report. Here's what investors should really have their eyes on.

A Closer Look at Multiple Sclerosis Treatments in 2014: BIIB, NVS, TEVA, SNY, RCPT

In 2014, the market for multiple sclerosis treatments could shift in favor of newer oral treatments. Let’s take a closer look at how Biogen, Novartis, Teva, Sanofi, and Receptos will fit into this changing market.

A Year-End Look at 3 High-Flying Biotech IPOs of 2013: PETX, RCPT, STML

Aratana Therapeutics Inc., Receptos Inc., and Stemline Therapeutics Inc. are three biotech IPOs of 2013 that are finishing the year with strong gains. Can they continue soaring into 2014?

This Week in Biotech: Part 2

With 11 noteworthy biotech events this week, Part 2 of this weekly series looks at six clinical updates that amazed investors, including a mid-stage cancer trial that sent shares of one company up 74% while a large pharmaceutical company chalked up another failure.

Why Receptos Inc. Shares Soared

Receptos shares vault higher after getting the A-OK from the independent data monitoring committee.

See More RCPT News...




RECEPTOS INC Website: http://www.receptos.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks